1-Methyl-5-glycyl barbituric Acid | 1027986-48-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Methyl-5-glycyl barbituric Acid
• 英文别名: 5-(2-Aminoacetyl)-1-methyl-1,3-diazinane-2,4,6-trione
• CAS: 1027986-48-6
• 化学式: C₇H₉N₃O₄
• 分子量: 199.166
• InChiKey: MYADUCSZNRIIOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Novel amino carboxy alkyl derivatives of barbituric acid
  申请人：——

  公开号：US20030199533A1

  公开（公告）日：2003-10-23

  The present invention relates to therapeutically active novel amino, carboxy, alkyl derivatives of barbituric acid of Formula (I), wherein at least one of R1, R2, R3 or R4 comprises an NH 2 moiety and at least one of R1, R2, R3 or R4 comprises one COOH moiety. Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

  本发明涉及一种具有治疗活性的巴比妥酸的新型氨基、羧基、烷基衍生物，其化学式为(I)，其中R1、R2、R3或R4中至少有一个包含一个NH2基团，而R1、R2、R3或R4中至少有一个包含一个COOH基团。本发明还提供了一种制备化合物(I)的方法，以及包含该化合物的制药组合物。这些新型化合物作为代谢型谷氨酸受体调节剂，因此在治疗与代谢型谷氨酸受体系统相关的中枢神经系统疾病方面具有用途。
• NOVEL AMINO CARBOXY ALKYL DERIVATIVES OF BARBITURIC ACID
  申请人：Curry, Kenneth

  公开号：EP1276727A1

  公开（公告）日：2003-01-22
• [EN] NOVEL AMINO CARBOXY ALKYL DERIVATIVES OF BARBITURIC ACID<br/>[FR] NOUVEAUX DERIVES AMINO CARBOXY ALKYLE D'ACIDE BARBITURIQUE
  申请人：CURRY KENNETH

  公开号：WO2001079185A1

  公开（公告）日：2001-10-25

  The present invention relates to therapeutically active novel amino, carboxy, alkyl derivatives of barbituric acid of Formula (I), wherein at least one of R1, R2, R3 or R4 comprises an NH2 moiety and at least one of R1, R2, R3 or R4 comprises one COOH moiety. Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.